<DOC>
	<DOCNO>NCT01232400</DOCNO>
	<brief_summary>The purpose study evaluate clinical effect esmolol treatment cardiac function electrophysiology ; assess effect esmolol treatment serum adrenergic cardiac biomarkers ; explore safety esmolol treatment shortly subarachnoid hemorrhage ( SAH ) . Patients follow maximum 1 month index SAH . The primary outcome change systolic function - ejection fraction Simpson 's rule ( baseline versus Day 7 +/- 2 SAH ) .</brief_summary>
	<brief_title>Study Evaluate Esmolol ( Brevibloc ) Manage Cardiac Function Patients With Subarachnoid Hemorrhage</brief_title>
	<detailed_description>Subarachnoid hemorrhage ( SAH ) remain one devastating form stroke . Over 25 % stroke relate potential year life lose SAH . Outcomes adversely affect secondary ischemia cerebral vasospasm , along cardiac complication . Trials perform patient SAH demonstrate benefit administration beta blocker - reduce mortality nearly half ; concern diminish cerebral perfusion inhibit widespread adoption therapy . Our specific aim follow : 1 . To evaluate clinical effect esmolol treatment cardiac systolic diastolic function , along cardiac electrophysiology ; 2 . To assess effect esmolol treatment serum adrenergic cardiac biomarkers ; 3 . To explore safety esmolol shortly SAH . The primary outcome change systolic function - ejection fraction Simpson 's rule ( baseline versus Day 7 +/- 2 SAH ) .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Subarachnoid Hemorrhage</mesh_term>
	<mesh_term>Esmolol</mesh_term>
	<criteria>Subarachnoid hemorrhage presume result rupture aneurysm Age 18 year old great Able enroll within 24 hour onset symptom Systolic blood pressure 140 mm Hg OR administration antihypertensives presentation Withdrawal life support imminent ( within six hour ) Known heart failure cardiomyopathy AND ejection fraction 35 % Prisoner pregnant female Ongoing vasopressor administration maintain SBP , clinical suspicion leave ventricular failure Clinically important arrhythmia ( history cardiac arrest ventricular arrhythmia ) , conduction abnormality ( Mobitz Type 2 , 3rd degree AV block , symptomatic Mobitz 1 without pacemaker ) , clinical cardiogenic shock , overt clinical heart failure Active bronchospastic disease ( ongoing bronchospasm SAH presentation current treatment oral corticosteroid asthma obstructive lung disease ) End stage renal disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>subarachnoid hemorrhage</keyword>
	<keyword>esmolol</keyword>
	<keyword>cardiac function</keyword>
	<keyword>cardiac electrophysiology</keyword>
</DOC>